investorscraft@gmail.com

Intrinsic ValueAgenus Inc. (AGEN)

Previous Close$4.33
Intrinsic Value
Upside potential
Previous Close
$4.33

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Agenus Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies designed to harness the body's immune system to fight cancer. The company operates in the highly competitive biopharmaceutical sector, leveraging its proprietary platforms to create novel antibody and cell therapy candidates. Agenus's core revenue model relies on strategic collaborations, licensing agreements, and milestone payments from partners, supplemented by grants and limited product sales. Its lead candidates, including botensilimab and balstilimab, target significant unmet needs in oncology, positioning the company as a niche player in the checkpoint inhibitor and T-cell engagement space. Agenus differentiates itself through a diversified pipeline and partnerships with larger biopharma firms, though its market position remains constrained by its clinical-stage status and reliance on external funding.

Revenue Profitability And Efficiency

Agenus reported revenue of $103.5 million for FY 2024, primarily driven by collaboration agreements and grants. The company's net loss widened to $227.2 million, reflecting high R&D expenditures and operational inefficiencies. With an operating cash flow of -$158.3 million and minimal capital expenditures, the firm remains heavily reliant on external financing to sustain its clinical programs.

Earnings Power And Capital Efficiency

The company's diluted EPS of -$10.59 underscores its lack of earnings power in the near term. Agenus's capital efficiency is challenged by its cash-intensive R&D model, with limited near-term prospects for profitability. The absence of commercialized products exacerbates its dependence on non-dilutive funding and partnership milestones.

Balance Sheet And Financial Health

Agenus's financial health is precarious, with $40.4 million in cash and equivalents against $94.9 million in total debt. The negative operating cash flow and high burn rate raise liquidity concerns, necessitating additional capital raises or strategic transactions to fund operations beyond the short term.

Growth Trends And Dividend Policy

Growth is contingent on clinical success and partnership monetization, with no dividends issued. The company's pipeline progression will dictate future revenue potential, though near-term losses are expected to persist given its developmental stage.

Valuation And Market Expectations

Market expectations are tied to clinical milestones and partnership announcements, with valuation reflecting high risk-reward dynamics typical of biotech firms. The absence of profitability metrics shifts focus to pipeline potential and binary catalysts.

Strategic Advantages And Outlook

Agenus's strategic advantages lie in its immuno-oncology expertise and collaborative partnerships, though execution risks remain high. The outlook hinges on clinical data readouts and the ability to secure additional funding or licensing deals to advance its pipeline.

Sources

Company filings, 10-K

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount